Alavert and Proteinuria aggravated - a phase IV clinical study of FDA data

Summary:

Proteinuria aggravated is found among people who take Alavert, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Alavert and have Proteinuria aggravated. It is created by eHealthMe based on reports of 1,801 people who have side effects when taking Alavert from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

1,801 people reported to have side effects when taking Alavert.
Among them, 18 people (1.0%) have Proteinuria aggravated.

What is Alavert?

Alavert has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 1,997 Alavert users for its effectiveness, alternative drugs and more.

What is Proteinuria aggravated?

Proteinuria aggravated is found to be associated with 1,090 drugs and 293 conditions by eHealthMe.

Number of Alavert and Proteinuria aggravated reports submitted per year:

Could Alavert cause Proteinuria aggravated?

Gender of people who have Proteinuria aggravated when taking Alavert *:

female: 94.44 %
male: 5.56 %

Age of people who have Proteinuria aggravated when taking Alavert *:

Common drugs people take besides Alavert *:

Common side effects people have besides Proteinuria aggravated *:

Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 17 people, 94.44%
Multiple Myeloma (cancer of the plasma cells): 17 people, 94.44%
Osteonecrosis Of Jaw (death of bone of jaw): 17 people, 94.44%
Osteolysis (dissolution of bone): 17 people, 94.44%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 17 people, 94.44%
Bone Disorder: 17 people, 94.44%
Neuralgia (pain in one or more nerves): 17 people, 94.44%
Bone Marrow Failure: 17 people, 94.44%
Bone Neoplasm (tumour of bone): 17 people, 94.44%
Breathing Difficulty: 17 people, 94.44%

Common conditions people have *:

Multiple Myeloma (cancer of the plasma cells): 15 people, 83.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.56%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 5.56%
Lung Cancer Metastatic (lung cancer spreads to other parts): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Alavert and have Proteinuria aggravated?

Check whether Proteinuria aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Proteinuria aggravated and when was it recovered:

Proteinuria aggravated in Alavert

Expand to all the drugs that have ingredients of loratadine:

Proteinuria aggravated and drugs with ingredients of loratadine

Alternative drugs to, pros and cons of Alavert:

Alavert (1,997 reports)

Common Alavert side effects:

Drug ineffective: 363 reports
High blood pressure: 109 reports
Dizziness: 107 reports
Fatigue (feeling of tiredness): 101 reports

Browse all side effects of Alavert:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Proteinuria aggravated treatments and more:

Proteinuria aggravated (10 reports)

COVID vaccines that are related to Proteinuria aggravated:

Common drugs associated with Proteinuria aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on loratadine (the active ingredients of Alavert) and Alavert (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.